The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials.

Date publication

juillet 2023

Journal

RMD open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BECKER Guillaume

Tous les auteurs :
Denis A, Sztejkowski C, Arnaud L, Becker G, Felten R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37507210

Résumé

The objective of this systematic review was to provide an overview of current developments and potentially available therapeutic options for spondyloarthritis (SpA) in the coming years.

Mots clés

ankylosing spondylitis, psoriatic arthritis, spondyloarthritis, therapeutics

Référence

RMD Open. 2023 07;9(3):